Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
706.03
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Analyst Ratings for argenx
↗
January 10, 2023
Via
Benzinga
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
↗
January 10, 2023
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in...
Via
Benzinga
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 09, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
argenx SE
Via
GlobeNewswire
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
↗
December 22, 2022
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading.
Via
Benzinga
Analyst Ratings for argenx
↗
December 07, 2022
Via
Benzinga
Expert Ratings for argenx
↗
December 07, 2022
Via
Benzinga
7 Analysts Have This to Say About argenx
↗
October 18, 2022
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
December 10, 2022
From
argenx SE
Via
GlobeNewswire
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
↗
November 30, 2022
Via
Benzinga
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 30, 2022
From
argenx SE
Via
GlobeNewswire
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder
↗
August 11, 2022
Via
Benzinga
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
↗
July 29, 2022
Via
Benzinga
argenx: Q2 Earnings Insights
↗
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
↗
November 22, 2022
Via
Benzinga
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 22, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
November 07, 2022
From
argenx SE
Via
GlobeNewswire
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
↗
October 28, 2022
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at...
Via
Benzinga
Recap: argenx Q3 Earnings
↗
October 27, 2022
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by...
Via
Benzinga
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022
From
argenx SE
Via
GlobeNewswire
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
↗
September 29, 2022
Via
Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
↗
September 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
↗
October 12, 2022
Upgrades
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
↗
August 11, 2022
Via
Benzinga
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
↗
August 11, 2022
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
↗
July 29, 2022
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
↗
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
